基于血浆蛋白质组学对肺动脉高压患者进行聚类分析
该研究纳入470例肺动脉高压患者、136例有症状疾病对照和59例健康对照作为发现队列,检测7288种血浆蛋白,筛选出156种区分肺动脉高压与两对照组的蛋白并进行无监督聚类,形成4个5年生存率各异的聚类;英国229例和法国79例独立验证队列证实聚类与生存相关,且PDGF通路在聚类3上调、TGF-β通路在聚类1上调。
要点
- 血浆蛋白质组可独立于临床分类将肺动脉高压分为4个聚类。
- 4个聚类5年生存率分别为78%、62%、44%和33%。
- 聚类3的PDGF通路和聚类1的TGF-β通路上调,可能作为靶向治疗的生物标志物。
核心结论
- 血浆蛋白质组谱可区分肺动脉高压的4个聚类,独立于临床分类,可能作为靶向PDGF和TGF-β通路新疗法的诊疗生物标志物。
研究设计与样本
- 发现队列纳入2013至2021年间470例肺动脉高压患者、136例有症状疾病对照和59例健康对照,采用SomaScan 7K平台检测7288种血浆蛋白。
- 对区分肺动脉高压与两对照组的蛋白进行无监督聚类(k-means聚类于UMAP降维维度),比较各聚类临床特征与结局。
- 英国229例和法国79例连续采样患者作为独立验证队列。
主要发现
- 156种血浆蛋白区分肺动脉高压与有症状疾病对照及健康对照,形成4个聚类。
- 4个聚类5年生存率分别为78%(聚类4)、62%(聚类2)、44%(聚类3)和33%(聚类1)。
- 验证队列中聚类与生存的关联证实了其区分度和临床相关性。
- 聚类3的PDGF通路上调程度高于其他聚类,聚类1的TGF-β通路上调。
关键数值与推荐
- 发现队列:470例肺动脉高压患者、136例有症状疾病对照、59例健康对照。
- 检测蛋白数:7288种;筛选出156种区分蛋白。
- 5年生存率:聚类4为78%,聚类2为62%,聚类3为44%,聚类1为33%。
- 验证队列:英国229例,法国79例。
临床怎么用
- 血浆蛋白质组聚类可能辅助肺动脉高压的分子分型,独立于临床分类。
- 聚类3和聚类1分别提示PDGF和TGF-β通路激活,可能指导靶向治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Patients with pulmonary hypertension are classified according to clinical criteria to inform treatment decisions. Knowledge of the molecular drivers of pulmonary hypertension might better inform treatment choice. Objectives: To investigate plasma protein clusters in patients with a diagnosis of pulmonary hypertension. Methods: Between 2013 and 2021, 470 patients with pulmonary hypertension, 136 control subjects with symptomatic disease, and 59 healthy control subjects were enrolled as a discovery cohort. Plasma levels of 7,288 proteins were assayed (SomaScan 7K platform). Proteins that distinguished pulmonary hypertension from both control groups were selected for unsupervised clustering (k-means clustering of Uniform Manifold Approximation and Projection dimensions). Clinical characteristics and outcomes were compared across clusters. Separate cohorts of serially sampled patients from pulmonary hypertension centers in the United Kingdom (n = 229) and France (n = 79) provided independent validation. Measurements and Main Results: A total of 156 plasma proteins that distinguished pulmonary hypertension from control subjects with symptomatic disease and healthy control subjects formed four clusters with diverse 5-year survival rates: 78% (cluster 4), 62% (cluster 2), 44% (cluster 3), and 33% (cluster 1). The distinction and clinical relevance of the clusters were confirmed in validation cohorts by their association with survival. To further characterize the therapeutic relevance of the clusters, we investigated two experimental drug targets: the PDGF (Platelet-Derived Growth Factor) pathway was upregulated in cluster 3 compared with other clusters, and the TGF-β (Transforming Growth Factor-β) pathway was upregulated in cluster 1. Conclusions: Plasma proteomic profiling of patients with pulmonary hypertension distinguishes four clusters, independent of the clinical classification. These groups, based on differential plasma protein levels, could act as theragnostic biomarkers for new therapies targeting PDGF and TGF-β pathways.
引用
- Boucly A, Song S, Keles M, et al. Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome. Am J Respir Crit Care Med. 2025. PMID: 40344188. doi:10.1164/rccm.202408-1574OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。